Skip to main content

Tay-Sachs Disease

0
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Rare Disease Therapeutics
1 program
A Natural History Study of the GangliosidosesN/A1 trial
Active Trials
NCT00668187Recruiting52Est. Mar 2027
Sanofi
SanofiPARIS, France
1 program
venglustat GZ402671PHASE_32 trials
Active Trials
NCT04705051Terminated24Est. Jul 2021
NCT04221451Terminated75Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Sanofivenglustat GZ402671
Sanofivenglustat GZ402671
Rare Disease TherapeuticsA Natural History Study of the Gangliosidoses

Clinical Trials (3)

Total enrollment: 151 patients across 3 trials

NCT04705051Sanofivenglustat GZ402671

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat

Start: Feb 2021Est. completion: Jul 202124 patients
Phase 3Terminated
NCT04221451Sanofivenglustat GZ402671

A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2

Start: Jun 2020Est. completion: Dec 202475 patients
Phase 3Terminated
NCT00668187Rare Disease TherapeuticsA Natural History Study of the Gangliosidoses

A Natural History Study of the Gangliosidoses

Start: Dec 2010Est. completion: Mar 202752 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 151 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.